Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment
Purpose: Several studies have provided evidence on the prognostic relevance of circulating tumor cells (CTCs) detected before and after chemotherapy regarding overall survival (OS) and progression-free survival (PFS) in early breast cancer (EBC). We provide data on the prevalence of CTCs 2 and 5 yea...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 June 2018
|
| In: |
Breast cancer research and treatment
Year: 2018, Jahrgang: 171, Heft: 3, Pages: 571-580 |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-018-4856-1 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/s10549-018-4856-1
|
| Verfasserangaben: | Emanuel C.A. Bauer, Fabienne Schochter, Peter Widschwendter, Amelie DeGregorio, Ulrich Andergassen, Thomas W.P. Friedl, Peter A. Fasching, Tanja Fehm, Andreas Schneeweiss, Matthias W. Beckmann, Klaus Pantel, Wolfgang Janni, Brigitte Rack, Christoph Scholz, on behalf of the SUCCESS Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1691751898 | ||
| 003 | DE-627 | ||
| 005 | 20251223024219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200305s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10549-018-4856-1 |2 doi | |
| 035 | |a (DE-627)1691751898 | ||
| 035 | |a (DE-599)KXP1691751898 | ||
| 035 | |a (OCoLC)1341309504 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bauer, Emanuel Christoph Alexander |d 1984- |e VerfasserIn |0 (DE-588)1132515831 |0 (DE-627)887835635 |0 (DE-576)488270006 |4 aut | |
| 245 | 1 | 0 | |a Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment |c Emanuel C.A. Bauer, Fabienne Schochter, Peter Widschwendter, Amelie DeGregorio, Ulrich Andergassen, Thomas W.P. Friedl, Peter A. Fasching, Tanja Fehm, Andreas Schneeweiss, Matthias W. Beckmann, Klaus Pantel, Wolfgang Janni, Brigitte Rack, Christoph Scholz, on behalf of the SUCCESS Study Group |
| 246 | 3 | 0 | |a two five |
| 264 | 1 | |c 21 June 2018 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.03.2020 | ||
| 520 | |a Purpose: Several studies have provided evidence on the prognostic relevance of circulating tumor cells (CTCs) detected before and after chemotherapy regarding overall survival (OS) and progression-free survival (PFS) in early breast cancer (EBC). We provide data on the prevalence of CTCs 2 and 5 years after primary diagnosis in a cohort of patients with EBC.Methods: The SUCCESS study is a multicenter, prospective, randomized trial comparing PFS in primary breast cancer patients undergoing one of two adjuvant chemotherapy regimens followed by 2 versus 5 years of treatment with zoledronate. CTCs from patients without signs of breast cancer recurrence were analyzed in peripheral blood using the FDA cleared CellSearch® System (Veridex, USA) 2 and 5 years after primary diagnosis. Results: CTCs were detected at 2 and 5 years after primary diagnosis in 96 (16.7%) and 47 (8.2%) of the 574 patients, respectively. There were no associations between CTC status and patient and tumor characteristics or treatment regimens. In 442 (77.0%) patients, no CTCs were detected at either of the two time points, and in 11 patients (1.9%), CTCs were found at both 2 and 5 years after primary diagnosis. In 85 (14.8%) patients, CTCs were present 2 years after primary diagnosis but not after 5 years, while 36 (6.3%) patients had CTCs in their blood only at the 5-year follow-up. Conclusions: In patients with EBC, CTCs can be detected even 5 years after primary diagnosis without clinical signs of disease recurrence. | ||
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d Dordrecht [u.a.] : Springer Science + Business Media B.V., 1981 |g 171(2018), 3, Seite 571-580 |h Online-Ressource |w (DE-627)320433722 |w (DE-600)2004077-5 |w (DE-576)104194162 |x 1573-7217 |7 nnas |a Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment |
| 773 | 1 | 8 | |g volume:171 |g year:2018 |g number:3 |g pages:571-580 |g extent:10 |a Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10549-018-4856-1 |x Verlag |x Resolving-System |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20200305 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 9 | ||
| 999 | |a KXP-PPN1691751898 |e 3603995945 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Bauer, Emanuel Christoph Alexander","family":"Bauer","role":"aut","given":"Emanuel Christoph Alexander"},{"family":"Schneeweiss","display":"Schneeweiss, Andreas","given":"Andreas","role":"aut"}],"note":["Gesehen am 05.03.2020"],"title":[{"title_sort":"Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment","title":"Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment"}],"language":["eng"],"recId":"1691751898","relHost":[{"language":["eng"],"id":{"issn":["1573-7217"],"eki":["320433722"],"zdb":["2004077-5"]},"note":["Gesehen am 02.12.05","Fortsetzung der Druck-Ausgabe"],"title":[{"title":"Breast cancer research and treatment","title_sort":"Breast cancer research and treatment"}],"pubHistory":["1.1981 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320433722","part":{"pages":"571-580","extent":"10","year":"2018","issue":"3","text":"171(2018), 3, Seite 571-580","volume":"171"},"disp":"Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatmentBreast cancer research and treatment","origin":[{"publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","publisher":"Springer Science + Business Media B.V. ; Kluwer","dateIssuedDisp":"1981-","dateIssuedKey":"1981"}]}],"origin":[{"dateIssuedDisp":"21 June 2018","dateIssuedKey":"2018"}],"name":{"displayForm":["Emanuel C.A. Bauer, Fabienne Schochter, Peter Widschwendter, Amelie DeGregorio, Ulrich Andergassen, Thomas W.P. Friedl, Peter A. Fasching, Tanja Fehm, Andreas Schneeweiss, Matthias W. Beckmann, Klaus Pantel, Wolfgang Janni, Brigitte Rack, Christoph Scholz, on behalf of the SUCCESS Study Group"]},"id":{"eki":["1691751898"],"doi":["10.1007/s10549-018-4856-1"]},"physDesc":[{"extent":"10 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a BAUEREMANUPREVALENCE2120 | ||